Related Experiment Video
Updated: Jan 31, 2026

Hydrolysis of a Ni-Schiff-Base Complex Using Conditions Suitable for Retention of Acid-labile Protecting Groups
Published on: April 6, 2017
Discovery of vanadium complexes bearing tridentate schiff base ligands as novel LSD1 inhibitors
Ling-Pan Lu1, Jin-Hai Liu1, Shi-Hong Cen1
1School of Pharmaceutical Sciences, Zhengzhou University of Industrial Technology, Zhengzhou 451199, PR China.
Abstract:
Lysine specific demethylase (LSD1) plays a pivotal role in epigenetic modulation of gene expression. Abberrant expression of LSD1 was associated with the progress and oncogenesis of multiple human cancers. Herein, we report the preliminary anti-LSD1 evaluation of the synthetic vanadium (V) complexes. Among them, complex 2 showed a moderate inhibitory effect against LSD1 with IC50 value of 19.0 μM, as well as good selectivity over MAO-A/B. Complex 2 is the first vanadium based LSD1 inhibitor, which provides a novel scaffold for the development of LSD1 inhibitor.
Insights
Researchers developed novel vanadium complexes as potential cancer drugs. Complex 2 moderately inhibited Lysine Specific Demethylase (LSD1), an enzyme linked to cancer, offering a new therapeutic avenue.
Area of Science:
- Biochemistry
- Epigenetics
- Medicinal Chemistry
Background:
- Lysine Specific Demethylase (LSD1) is crucial for epigenetic gene regulation.
- Aberrant LSD1 expression correlates with human cancer progression and oncogenesis.
Purpose of the Study:
- To evaluate synthetic vanadium (V) complexes as potential inhibitors of LSD1.
- To explore novel therapeutic scaffolds for targeting LSD1 in cancer treatment.
Main Methods:
- Synthesis and characterization of novel vanadium (V) complexes.
- In vitro evaluation of inhibitory activity against LSD1.
- Selectivity assessment against Monoamine Oxidase A/B (MAO-A/B).
Main Results:
- Complex 2 demonstrated moderate inhibitory activity against LSD1 with an IC50 of 19.0 μM.
- Complex 2 exhibited good selectivity over MAO-A/B.
- This marks the first report of a vanadium-based LSD1 inhibitor.
Conclusions:
- Vanadium complex 2 represents a novel class of LSD1 inhibitors.
- The findings provide a new scaffold for developing targeted cancer therapies by inhibiting LSD1.
More Related Videos
07:20Amide Coupling Reaction for the Synthesis of Bispyridine-based Ligands and Their Complexation to Platinum as Dinuclear Anticancer Agents
Published on: May 28, 2014
10:33Development of Inhibitors of Protein-protein Interactions through REPLACE: Application to the Design and Development Non-ATP Competitive CDK Inhibitors
Published on: October 26, 2015
Related Concept Videos
Metal-Ligand Bonds
In these complexes, transition metals form coordinate covalent bonds, a kind of Lewis acid-base interaction in which both of the electrons in the bond are contributed by a donor (Lewis base) to an electron acceptor (Lewis acid). The Lewis acid in...
Ligand Binding Sites
Protein-ligand interactions are quite specific; even though numerous potential ligands surround a cellular protein at any given time, only a particular ligand can bind to that protein. Moreover, a ligand binds only to a dedicated area on the surface of the protein, known as the...
Formation of Complex Ions
Ligand Binding and Linkage
Crystal Field Theory - Octahedral Complexes
To explain the observed behavior of transition metal complexes (such as colors), a model involving electrostatic interactions between the electrons from the ligands and the electrons in the unhybridized d orbitals of the central metal atom has been developed. This electrostatic model is crystal field theory (CFT). It helps to understand, interpret, and predict the colors, magnetic behavior, and some structures of coordination compounds of transition metals.
CFT focuses on...
Eukaryotic Transcription Inhibitors
Eukaryotic transcription inhibitors usually contain two distinct domains, a...